Acne Treatment With Active Oplon's Patches - 15-18 Years Old
The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2010 by Oplon-Pure Science Ltd..
Recruitment status was Not yet recruiting
Recruitment status was Not yet recruiting
Sponsor:
Oplon-Pure Science Ltd.
Information provided by:
Oplon-Pure Science Ltd.
ClinicalTrials.gov Identifier:
NCT01260766
First received: December 14, 2010
Last updated: December 16, 2010
Last verified: December 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study was to demonstrate the effect of short treatment with active OPLON patches on Acne.
| Condition | Intervention | Phase |
|---|---|---|
|
Acne Vulgaris |
Device: Oplon Active Patch Device: Placebo Patch |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Phase II- Acne Treatment With Active Patches Which Contains Azelaic Acid, Citric Acid,Salicylic Acid and 2% Ascorbic Acid |
Resource links provided by NLM:
Further study details as provided by Oplon-Pure Science Ltd.:
Primary Outcome Measures:
- Severity Score of lesion [ Time Frame: Severity Score of lesion [Time Frame: 24 hours following patch removal] ] [ Designated as safety issue: No ]
Lesions were ranked by investigator according to severity whereas:
0-clear, 1-mild, 2-moderate, 3-sever
Secondary Outcome Measures:
- Severity Score of lesion [ Time Frame: Severity Score of lesion [Time Frame: 12 hours with the patch] ] [ Designated as safety issue: No ]
Lesions were ranked by investigator according to severity whereas:
0-clear, 1-mild, 2-moderate, 3-sever
| Estimated Enrollment: | 50 |
| Study Start Date: | January 2011 |
| Estimated Study Completion Date: | June 2011 |
| Estimated Primary Completion Date: | April 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: Active Comparator: Oplon Active Patch |
Device: Oplon Active Patch
Patches are placed over acne lesion overnight. Treatment is a single treatment.
|
| Placebo Comparator: Placebo Comparator: Placebo patch |
Device: Placebo Patch
same as active patch
|
Detailed Description:
Patients with Acne Vulgaris were treated overnight with active patches. Effect is observed at the end of the treatment and 24 hours later.
Eligibility| Ages Eligible for Study: | 15 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Acne Vulgaris
- Over 15 years
- Signing informed consent
Exclusion Criteria:
- Active treatment of acne
- Change in hormonal therapy
- Antibiotic treatment in a week prior to the experiment
- Sensitive skin
- Pregnancy
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01260766
Contacts
| Contact: Avner Shemer, M.D. | : +972-524575677 | ashemer1@gmail.com |
Locations
| Israel | |
| Dermatology Clinic | Recruiting |
| Natanya, Israel | |
| Contact: Avner Shemer, M.D. +972-524575677 ashemer1@gmail.com | |
Sponsors and Collaborators
Oplon-Pure Science Ltd.
Investigators
| Principal Investigator: | Avner Shemer, M.D. | Laniado Medical Center |
More Information
No publications provided
| Responsible Party: | Avner Shemer M.D., Dermatology Clinic |
| ClinicalTrials.gov Identifier: | NCT01260766 History of Changes |
| Other Study ID Numbers: | OP003 |
| Study First Received: | December 14, 2010 |
| Last Updated: | December 16, 2010 |
| Health Authority: | Israel: Ethics Commission |
Additional relevant MeSH terms:
|
Acne Vulgaris Acneiform Eruptions Skin Diseases Facial Dermatoses Sebaceous Gland Diseases |
Benzoyl Peroxide Dermatologic Agents Therapeutic Uses Pharmacologic Actions |
ClinicalTrials.gov processed this record on June 18, 2013